Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943126 | 1.00 | MEN1 (0.63) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL26382685 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768806 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768947 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL18768810 | 0.89 | CASP2 (0.52) | MEN1KMT2ACASP2NAAAFAAH | |
| SCHEMBL22619964 | 0.87 | CASP2 (0.67) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL20848160 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL19704868 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL18769027 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL19704886 | 0.86 | CASP2 (0.47) | MEN1KMT2ACASP2NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-9644195-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9200268-B2 | Compounds and methods for purification of serine proteases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2015-11-26 | — | — | US | disclosed |
| US-20140346397-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) | 2014-11-27 | — | — | US | disclosed |
| US-20140186923-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337285-A1 | COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES | PRSS1, HPN, PRSS8 | MEN1 2051/4885KMT2A 4388/4885CASP2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.